7AY1 Stock Chart & Stats
€0.71
>-€0.01(-0.14%)
At close: 4:00 PM EDT
€0.71
>-€0.01(-0.14%)
Day’s Range― - ―
52-Week Range€0.63 - €1.50
Previous CloseN/A
Volume0.00
Average Volume (3M)100.00
Market Cap
€29.13M
Enterprise Value-€8.61M
Total Cash (Recent Filing)€36.47M
Total Debt (Recent Filing)€1.34M
Price to Earnings (P/E)2.8
Beta0.71
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,441,437
10 Day Avg. Volume138
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.00Price Target Upside322.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.1
Revenue Forecast (FY)€30.26M
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings ImprovementThe sharp improvement in revenue and reported profitability indicates meaningful progress in commercialization or funding-related activities. If sustained, it could strengthen operating scale and support continued development, although consistency remains unproven.
Low Leverage And Stronger CapitalizationA lightly levered balance sheet limits interest and refinancing pressure, while higher equity improves capitalization relative to prior periods. This provides greater financial flexibility for a clinical-stage company, even though ongoing cash burn remains a constraint.
Actimab-A Platform ExpansionBroader intellectual-property protection can extend the platform’s commercial defensibility, while added manufacturing capacity supports clinical execution. Expansion into solid-tumor applications and upcoming milestones could diversify the pipeline beyond the initial AML focus.
Bears Say
Persistent Cash BurnNegative operating and free cash flow shows that reported earnings are not yet translating into self-funded operations. Continued development spending may require additional financing, creating dilution or liquidity risk if cash burn persists over the medium term.
Thin And Volatile ProfitabilityVery low gross profitability limits the company’s ability to absorb development and operating costs, while prior-year volatility reduces confidence in earnings durability. The recent profit swing may not represent a stable commercial model until margins improve materially.
NYSE American Compliance RiskThe remediation period preserves exchange access but does not resolve the underlying equity-based compliance issue. Failure to restore compliance could lead to delisting, reduce market access, and complicate future capital raising for pipeline development.
Actinium Pharmaceuticals News
7AY1 FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was €0.63 and its highest was €1.50 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is €29.13M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Nov 23, 2026 which is in 88 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -€0.165 earnings per share for the quarter, missing the consensus estimate of -€0.162 by -€0.003.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,441,437 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -€0.165 in its last earnings report, missing expectations of -€0.162. Following the earnings report the stock price went up 0.612%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:7AY1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actinium Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.28%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
7AY1 Stock 12 Month Forecast
Average Price Target
€3.00
▲(322.00% Upside)
Technical Analysis
Cellectar Biosciences
―
PDS Biotechnology
―
GT Biopharma
―
Marker Therapeutics
―
Celularity
―